Sweet Kendra, Lancet Jeffrey E
, 12902 Magnolia Dr, FOB3-Heme, Tampa, FL, 33612, USA,
Curr Hematol Malig Rep. 2014 Jun;9(2):109-17. doi: 10.1007/s11899-014-0199-0.
Acute myeloid leukemia (AML) is a heterogenous disease, and the standard treatment with cytotoxic chemotherapy has remained largely unchanged for over four decades. As more is being learned about AML and the potential molecular targets found within the leukemia cells, an abundance of targeted therapies are becoming available for study in the treatment of this challenging disease. This review serves to provide a brief overview of some of several agents currently being studied and developed in AML.
急性髓系白血病（AML）是一种异质性疾病，细胞毒性化疗的标准治疗在四十多年来基本没有变化。随着对AML以及白血病细胞内潜在分子靶点的了解越来越多，大量靶向疗法正可供研究用于治疗这种具有挑战性的疾病。本综述旨在简要概述目前正在AML中研究和开发的几种药物中的一些。
